Company ProfilePremium

Yashili International Holdings Ltd

Company Profile Analysis

ESOMAR 23 Corporate BadgeISO Certifications Badge
Yashili International Holdings Ltd - Company showcase

Year Founded & Workforce

1983

Yashili International Holdings Ltd logo

Yashili International Holdings Ltd Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Yashili International Holdings Ltd Overview

Yashili was one of China's earliest domestic infant-formula brands. It was founded in Chaozhou, Guangdong, and listed in Hong Kong as a pure-play producer of infant milk formula (IMF) and nutrition foods. After Mengniu took control in 2013, Yashili became the vehicle for Mengniu's formula ambitions. Its multi-brand portfolio covered the Yashili-branded mass range, the premium Reeborne (瑞哺恩) line, the goat-milk range Doraler, the acquired Dumex (多美滋) China business, and distribution of Arla's Baby&Me and Milex brands. It also built a New Zealand manufacturing base at Pokeno. Despite these assets, the company lost ground through China's 2017 formula-registration regime, falling births, and premiumisation led by Feihe and the multinationals. It slipped from a top-seven national brand in 2006–2013 to outside the top ten by 2021. The company was privatised in 2023 as Mengniu and Danone unwound their partnership. Today Yashili is an operating unit inside Mengniu: Reeborne is its growth brand, the non-core assets (Dumex, the Arla distribution, Yashili NZ) have been divested, and the Guangdong and Shanxi plants remain.


Company's own description (latest listed filings). Yashili described itself as a domestically leading professional infant-formula producer with an international presence, focused on producing and selling premium infant formula and nutrition food (paraphrased from the 2022 transaction disclosures, as summarised by Zhong Lun, 2022). MarketScreener's profile summarises the company as an investment holding company that manufactures and sells dairy and food products, reported across five segments.

Business model. Yashili was a branded consumer-products manufacturer. Revenue was almost entirely product sales: no subscription or licensing revenue of note was disclosed. Distribution income came from selling third-party Arla brands between 2016 and 2022. Value was captured through:

  1. Formula registration rights. Under China's SAMR formula-registration regime, each plant may hold a limited number of registered "series." Registrations are scarce, tradable assets; the Pokeno plant's two China-label registrations were the core of the 2025 sale to a2.

  2. Brand premium, strongest in super-premium and organic tiers (Reeborne, Dumex, Arla Baby&Me Organic).

  3. Channel reach across mother-and-baby (MBS) specialty stores, modern trade, and e-commerce. Arla noted that MBS stores were 69% and e-commerce 25% of China's early-life-nutrition market in 2021 (Arla press release, 2022).

Value-chain position. Yashili was a midstream processor and brand owner. It did not own dairy farms; it bought raw milk and imported base powders. In New Zealand, Yashili NZ ran a single site at Pokeno without its own farms (dairynews.today, 2025). This made gross margin sensitive to global whole-milk-powder and whey prices.

Customer types. Customers were distributors and MBS chains, e-commerce platforms (Tmall, JD), and supermarkets. End consumers are parents of infants aged 0–36 months, plus adults and seniors for adult milk powder and nutrition products.

End-markets. End-markets were the Chinese infant-formula market (the vast majority of revenue), adult and senior milk powder, rice cereal and nutrition supplements, and small export and Hong Kong sales.

Independent characterisation. Yashili had good assets but a weak strategic position. It had registered plants, an early mover's brand awareness in lower-tier cities, and Mengniu's channel support. It never solved its brand-positioning problem in the premium tier and suffered repeated management turnover. Industry analyst Song Liang attributed its decline to missing the 2017–2018 registration window and to unstable sales leadership without good incentive structures (Jiemian, 2022). Post-privatisation, Mengniu has concentrated the business on Reeborne. Mengniu's FY2025 results presentation credits Reeborne with launching China's first infant formula containing Sn-2 DHA & ARA and achieving robust growth.

Strategy

Last listed-era strategy (2020–2022 Annual Reports, paraphrased themes).

  1. Brand focus on Reeborne as the national premium IMF brand, with a breast-milk-research narrative.

  2. SKU rationalisation. Low-value, low-margin SKUs were cut, with management stating Q2 2020 revenue grew about 25% YoY after the restructuring (Jiemian, 2020).

  3. Channel restructuring toward MBS and e-commerce, supported by Mengniu's distribution.

  4. Portfolio simplification. The Arla distribution was exited in 2022–23 so Yashili could focus on its remaining portfolio (Arla press release).

Post-privatisation strategy (inside Mengniu).

Rationale: Privatisation was intended to let Mengniu restructure its formula assets, streamline operations and capture synergies (Jiemian English, 2023). Analysts noted it also removed connected-transaction and competition constraints, so Mengniu could integrate or acquire further formula brands (Jiemian, 2022).

Mengniu's "R&D-driven, brand-led" formula strategy (FY2025): The strategy centres on Reeborne innovations: Sn-2 DHA/ARA in 2025, then organic MLCT infant formula and breast-milk nutrition work in 2026. A second focus is precision nutrition for middle-aged and older consumers.

Asset monetisation: Yashili NZ was sold to a2 (2025), monetising the two China-label registrations at about NZ$275–282M.

Historical target: Mengniu's 2020 "create a new Mengniu in five years" plan targeted RMB 10bn of formula revenue within three years and over RMB 10bn by 2025 (Sina; Jiemian). Actual FY2022 formula revenue was RMB 3.86bn, so the target was missed by a wide margin.

Medium-term targets. No Yashili-specific targets are publicly disclosed. Mengniu has a 2025–2027 shareholder-return plan, but no formula-specific guidance beyond qualitative statements.

ESG commitments. Covered at Mengniu group level.

Products & Services

Pricing model. Retail premium pricing; specific price points are not publicly disclosed by the company. Two China-label IMF registrations were attached to the Pokeno plant (a2MC, 2025). The number of SAMR registered series held by the Guangdong and Shanxi plants is not publicly disclosed in sources reviewed.

Product Portfolio

Brand / lineSegmentDescription & positioningTarget customerLaunch / latestStatus (Oct 2026)

Reeborne (瑞哺恩)

Milk powder

Premium-to-super-premium IMF positioned on breast-milk-like nutrition. July 2020 relaunch introduced the "亲乳" (close-to-breastmilk) series: 7 SKUs across mainstream cow-milk, organic and goat-milk formula, with a lighter taste and broader nutrient profile (Jiemian, 2020)

Urban and lower-tier parents, infants 0–36 months

Relaunched Jul 2020. 2025: first IMF with Sn-2 DHA & ARA. 2026: organic MLCT infant formula (Mengniu presentations)

Core growth brand within Mengniu

Yashili (雅士利)

Milk powder

Legacy mass and mid-tier IMF and growing-up milk; China-label products historically also made at Pokeno

Value-conscious families, lower-tier cities

Brand since 1980s

Ongoing (scale not disclosed)

Doraler (朵拉小羊)

Milk powder

Goat-milk infant formula sub-brand

Parents seeking goat-milk alternatives

Cited in 2021 portfolio (Jiemian, 2023)

Status not publicly disclosed

Dumex (多美滋)

Milk powder

Former Danone multinational brand bought in 2015. Sales fell 68.3% to USD 64.6M in 2015 (CCM). Dumex China had post-tax profit of RMB 12M in 2021 vs RMB 40M in 2020 and net assets of −RMB 11M (Jiemian, 2022)

Premium segment

Acquired Dec 2015

Divested to Danone in 2022–23 special deals

Arla Baby&Me Organic / Baby&Me Blue Dawn / Milex

Distribution

Arla-owned imported formula, distributed by Yashili under agreement from 2016

Organic and imported-formula buyers

2016–2023

Transferred to Arla (completed Sep 2023)

Mengniu-branded adult / senior milk powder

Other milk powder

Adult, middle-aged and senior nutrition milk powders

Adults, seniors

Ongoing

Mengniu emphasises precision nutrition for middle-aged and older consumers (2026 interim)

Nutrition / brewing products (冲调)

Nutrition

Rice cereal, drink powders and complementary nutrition foods

Infants (complementary feeding), families

Ongoing

FY2022 revenue RMB 195M

a2 English-label formula (contract manufacture)

Others / NZ

Pokeno co-developed and produced a2 Gentle Gold and a2 Genesis for The a2 Milk Company

a2 (B2B)

Pre-2025

Plant sold to a2 (Sep 2025)

Financial Narrative

All figures in RMB million unless stated. IFRS.

Income statement

Sources: FY2022 Annual Results Announcement (29 Mar 2023) for FY2021–FY2022; PEdaily/TMTPost (2023) for FY2020 revenue and growth; Jiemian (2022) for FY2018–FY2020 net profit. FY2019 revenue is derived from FY2020 revenue and the disclosed +6.95% growth. FY2022 EBITDA was disclosed as a loss in the results announcement, but the figure was not captured; see the FY2022 Annual Report.

Per-share data (RMB cents)

FY2018–FY2020 EPS derived as net profit ÷ 4,745.56M shares. FY2021–FY2022 reported (FY2022 Results Announcement). No special dividend proposed for FY2021 or FY2022.

Margins

Derived: Revenue CAGR. FY2019–FY2022 ≈ +3.1% (3,412 → 3,738; derived). FY2014–FY2022 ≈ +0.6% (3,554 → 3,738). The longer view is effectively a decade of stagnation, against a FY2012 peak of RMB 3.65bn.

Interim snapshots

Sources: 2022 Interim Results Announcement; Jiemian (Aug 2020).

Balance sheet

Source: FY2022 Results Announcement. The group carried large net assets relative to market value; the HK$1.20 offer implied about 0.9x FY2022 book at contemporaneous FX. Finance income of RMB 31.7M in H1 2022 points to a meaningful net cash position, but the exact cash and debt balances are not captured here and should be confirmed in the FY2022 Annual Report.

Cash flow

Source: FY2022 Results Announcement (operating cash outflow worsened 87.4%).

Commentary

Trend. Yashili's financial history has three phases. The first is the boom to FY2012: revenue of RMB 3.65bn and net profit of RMB 470.5M. The second is collapse and impairment, FY2014–FY2017: revenue fell to RMB 2.2bn by FY2016, followed by losses of RMB 320M and RMB 180M. Mengniu wrote off about RMB 2.25bn of goodwill in 2016. The third is a thin-margin recovery, FY2018–FY2021. FY2021's 21.5% revenue jump to RMB 4.43bn was the best top-line year in the company's history. It nonetheless ended in a loss after a Dumex impairment of up to RMB 300M.

Inflection in 2022. FY2022 revenue fell 15.7%. Gross margin compressed by 4.8 percentage points to 28.1%, which management linked to the interim gross-margin decline. Operating cash flow deteriorated to −RMB 495M. A sub-scale player with high fixed sales and marketing costs saw negative operating leverage.

Drivers. The main drivers were demographic contraction, formula re-registration costs, raw-material inflation in 2021–22, impairment of acquired brands (Dumex), and structural MBS channel destocking.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment

Segment (CNY Mn)FY2020FY2021FY2022

Milk powder products

—3,6512,968

Other milk powder products (derived residual)

—438512

Nutrition / brewing products (冲调)

—221195

Others

—12563

Total revenue

3,6494,434.73,738.2

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Results by Segment

Metric (CNY Mn)H1 2021H1 2022

Segment result – Segment 1 (milk powder)

126.4-31.9

Segment result – Segment 2

4.41.8

Segment result – Segment 3

15.87.5

Segment result – Segment 4

6.51.1

Total segment results

153.1-21.6

Group revenue

2,156.91,886.7

Segment Overview

SegmentFY2022 revenue (CNY Mn)% of totalYoY

Milk powder products

2,96879.4%-18.7%

Other milk powder products (derived)

51213.7%

positive (stated as growing)

Nutrition / brewing products

1955.2%-11.8%

Others

631.7%-49.3%

Total

3738.2

100%

-15.7%

Revenue by Segment (Half-Yearly)

Metric (CNY Mn)H1 2019H1 2020

Milk powder segment revenue

1,398.71,290.1

Revenue by Segment (FY2018–FY2022)

Metric (CNY Mn)FY2018FY2019FY2020FY2021FY2022

Mengniu milk powder revenue (incl. Yashili, Bellamy's; FY2018–19 also incl. Junlebao-era effects)

6,0177,8704,5734,9493,862

Revenue by Segment (H1 2025–H1 2026)

Metric (CNY Mn)H1 2025H1 2026

Mengniu Milk Formula revenue

1,6762,058

Income Statement

Metric (CNY Mn)FY2018FY2019FY2020FY2021FY2022

Revenue

—3,4123,6494,434.73,738.2

Gross profit

———1,460.01,050.3

Operating profit (loss)

———-144.8-229.4

Pre-tax profit (loss)

———-93.1-202.9

Net profit (loss)

52112101-81.4-230.7

Total comprehensive income (loss)

———-195.7-212.3

Per-Share Data

Metric (MYR Bn cents)FY2018FY2019FY2020FY2021FY2022

Basic EPS

1.12.42.1-1.7-4.9

Diluted EPS

———-1.7-4.9

Dividend per share

———00

Net asset value per share (MYR Bn)

———1.21.1

Margin Analysis (%)

Metric (%)FY2019FY2020FY2021FY2022

Gross margin

——32.928.1

Operating margin

——-3.3-6.1

Pre-tax margin

——-2.1-5.4

Net margin

3.32.8-1.8-6.2

Income Statement and Per-Share Data

Metric (CNY Mn)H1 2019H1 2020H1 2021H1 2022

Revenue

1,747.41,644.92,156.91,886.7

Gross profit

——815.3596.7

Pre-tax profit (loss)

——43.8-145.9

Attributable profit (loss)

34.335.6——

Basic EPS (MYR Bn cents)

——0.9-3.4

Finance income

——39.131.7

Liquidity & Coverage Ratios

Metric (CNY Mn)FY2021FY2022

Net assets (total equity)

5,528.15,316.0

Net current assets (working capital)

1,938.42,343.3

Cash Flow

Metric (CNY Mn)FY2021FY2022

Net operating cash flow

-264.4-495.4

Dividends paid

00

Buybacks

00

Returns & Leverage Ratios (%)

RatioFY2021FY2022

ROE (net result ÷ year-end equity, %)

-1.5-4.3

Revenue by Region

Region (revenue)FY2022FY2023FY2024

Yashili New Zealand Dairy revenue (NZD Mn)

157.392.057.9

Yashili New Zealand Dairy net loss (NZD Mn)

—25.723.5

Region Overview

RegionSplitComment

Mainland China

≈95%+ (estimate based on business mix; not disclosed)

Core market; declining with births

New Zealand (manufacturing / export)

Not disclosed at group level

Declining; sold Sept 2025

Capital Markets

ItemDetail

Listing status

Delisted ~5 July 2023; no trading

Final exit price

HK$1.20 per share cash (scheme cancellation price)

Implied equity value

≈HK$5,695M (derived)

Price to FY2022 book

≈0.9x (HK$1.20 vs NAV RMB 1.1/share; FX-dependent, derived)

1/3/5-year share price performance

Not applicable (no quotation after July 2023)

Valuation multiples (P/E, EV/EBITDA)

Not meaningful: loss-making at exit

Analyst consensus

None (no coverage)

Dividend history

No dividends for FY2021 or FY2022; earlier history not captured

Credit ratings

None (no rated debt); parent Mengniu ratings apply at group level

Components

Component (HKD Mn)Value

Scheme consideration to minorities

1,370

Danone 25% stake purchase

1,400

Aggregate cash outlay by Mengniu (privatisation + Danone shares)

2,790

Analyst Conclusions

Management guidance. No Yashili-level guidance exists. Mengniu presents its formula business as R&D-driven and brand-led. It highlights Reeborne's product leadership, a 22.8% H1 2026 revenue rebound, and overseas expansion. Mengniu's group priorities are stabilising ambient liquid milk, growing cheese, fresh milk and formula, and delivering its 2025–2027 shareholder-return plan.

Bull case.

  1. Growth has returned. Formula revenue grew 22.8% in H1 2026, with infant formula described as leading the industry. The rebound off a depressed 2023–2025 base, combined with Reeborne's innovation cadence, could restore the business toward its FY2021 peak of about RMB 4.4bn.

  2. A cleaner portfolio. Dumex, the Arla distribution and the loss-making NZ plant are gone. The NZ unit alone had lost NZ$23.5–25.7M a year, so the remaining Guangdong and Shanxi operations should carry a better cost structure.

  3. Group synergies without listed-company constraints. Mengniu's procurement, channels and lactoferrin and deep-processing capabilities can now be applied without connected-transaction friction.

Bear case.

  1. Structural demand decline. Births have roughly halved since 2016, and Yili (18.1% share) and Feihe dominate. A sub-scale player faces permanent pricing pressure.

  2. History of value destruction. More than RMB 2bn of Dumex losses, about RMB 2.25bn of goodwill impairment, and the miss on Mengniu's RMB 10bn formula target argue against a durable turnaround.

  3. Divested assets now fund competitors. The ex-Yashili China-label registrations will relaunch under a2, and Arla is reinvesting in the brands Yashili once sold.

Catalysts and monitorables (next 12 months).

  • Mengniu FY2026 results (March 2027): full-year formula revenue and margin.

  • Reeborne market-share data from Nielsen or Kantar retail panels.

  • a2's SAMR approval for the relaunched ex-Pokeno registrations, a direct new competitor.

  • Effects of China's birth-support and childcare-subsidy policy on 2026–27 births.

  • Any Mengniu consolidation of formula entities (Yashili, Bellamy's) or further formula M&A.

  • Raw-milk price cycle and China Modern Dairy's financial health.

Analyst verdict. Yashili International Holdings no longer exists as an investable security. Mengniu completed a cash privatisation at HK$1.20 per share in July 2023, roughly 0.9x book, after a decade in which the company never recovered its FY2012 peak profitability. Any assessment today is really an assessment of a business unit inside China Mengniu Dairy and of Mengniu's formula strategy.

The listed-era record is poor. Revenue stagnated around RMB 3.4–4.4bn from FY2014 to FY2022, net margins never exceeded about 3% after FY2015, and the company ended its public life with a RMB 230.7M loss and a RMB 495M operating cash outflow. Its largest strategic bets failed or were reversed: Dumex was bought from Danone and sold back to it, Danone's equity alliance was unwound, the Arla distribution passed to Arla, and the Pokeno plant went to a2. Each exit simplified the business, but each also handed a competitor an asset.

What remains is more focused than it has been in years: two registered Chinese plants, a single hero brand (Reeborne) with a credible innovation pipeline, and an owner with national scale. The H1 2026 rebound in Mengniu's formula revenue (+22.8%) is the first clear evidence that the post-privatisation reset may be working. Some of that rebound reflects a low base and industry-wide stabilisation rather than share gains.

Our judgement is cautiously neutral. The business is now strategically rational, with low listed-company overhead and fewer distractions. It remains structurally sub-scale in a shrinking category dominated by Yili and Feihe. For investors, exposure exists only through Mengniu (2319.HK), where formula is under 5% of revenue and unlikely to drive group valuation. The key test over the next 12–18 months is whether Mengniu's formula line can sustain double-digit growth after the base effect fades.


Source list (primary and secondary documents referenced)

  • Yashili International Holdings Ltd — Annual Results Announcement FY2022 (HKEX, 29 Mar 2023); Interim Results H1 2022 (HKEX, 24 Aug 2022); Annual Report 2020 (HKEX, 20 Apr 2021); Annual Report 2012 (HKEX, 25 Apr 2013)

  • Joint Mengniu/Yashili announcements on privatisation (HKEX, 23 Jun, 30 Jun and 5 Jul 2023)

  • China Mengniu Dairy — 2025 Annual Results presentation and announcement; Annual Report 2025; 2026 interim presentation; press release 26 Mar 2026

  • The a2 Milk Company — FY25 results and Pokeno acquisition disclosures (via ChemLinked, Just Food, NutraFoods Spectrum, Inside FMCG, Food & Drink Business)

  • Arla Foods — press release on acquisition of China IMF business (2022)

  • Zhong Lun Law Firm (2022, 2023); Norton Rose Fulbright (May 2022)

  • MarketScreener / Zonebourse Yashili news registers

  • Jiemian (2020, 2022, 2023); PEdaily/TMTPost (2023); Sina Finance (2023); Beijing Business Today (2023); CCM (2016); just-food (2013); dairynews.today (2025); DairyReporter; Tiger Brokers / Deep News (2026); Dairy Business MEA (2025, 2026); Emperor Capital (Mar 2026)

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameRoleTenureNotesCompensation

Yan Zhiyuan (闫志远)

Executive President, Yashili International

From Jan 2020 (appointed 8 Jan 2020 per 2020 Annual Report; MarketScreener lists CEO age 43 from 08/01/2020)

Led the Reeborne relaunch (2020)

—

(Name not captured)

CFO

From Dec 2020; appointed from Mengniu

Replaced the departing CFO

—

Gao Fei (高飞)

CEO & Executive Director, China Mengniu Dairy (parent)

Current (FY2025 results)

Leads group formula strategy

See Mengniu Annual Report 2025

Chen Yiyi

Vice President, China Mengniu Dairy

Current

Spokesperson on overseas business, FY2025

See Mengniu Annual Report 2025

“—” = not publicly disclosed.

Shareholding Trend

HolderStake before Mar 2023Stake after Mar 2023Stake after Jul 2023

Mengniu International (Mengniu)

2,422,117,713 shares (≈51.0%)

≈51.0%

Combined 100% with offeror

Danone Asia Baby Nutrition Pte Ltd

≈25%

0 (sold to Mengniu for ≈HK$1.4bn)

0

Star Future Investment (Mengniu offeror)

—

≈25%

Combined 100%

Public / scheme shareholders

≈24% (scheme shares ≈23.96%)

≈23.96%

0 (cancelled at HK$1.20)

Competitive Landscape

Key Competitors

CompetitorTypeComparative revenuePositioning vs. Yashili

China Feihe

Domestic leader

RMB 18,592M (2020)

Dominant premium domestic brand; net profit RMB 7,437M (2020), about 70x Yashili's

Yili (Pro-Kido 金领冠)

Domestic dairy major

Milk powder ranked No.1 in China in 2025; group revenue RMB 115.9bn (2025)

Leader; vertically integrated milk supply

Junlebao

Domestic

RMB 14,468M (2020, total company)

Former Mengniu associate; mass-premium

Ausnutria

Domestic (goat milk leader)

RMB 7,986M (2020)

Goat-milk leadership vs Doraler

Biostime (H&H Group)

Domestic / premium

Not captured

Premium MBS channel

Nestlé (Wyeth Illuma)

Multinational

Not captured

Super-premium leader

Danone (Aptamil, Dumex)

Multinational

Not captured

Super-premium; now owns Dumex again

a2 Milk Company

Foreign

NZ$1,902M group (FY2025); China-label IMF NZ$632.5M

Now owns ex-Yashili Pokeno registrations

Beingmate

Domestic

Not captured

Similar mid-tier struggles

Abbott, FrieslandCampina, Arla

Multinationals

Not captured

Arla took over the brands Yashili distributed

Peer Comparison FY2024

MetricYashiliFeiheJunlebaoAusnutria

Revenue

3,64918,59214,4687,986

Net profit

1017,4375381,004

Net margin (%)

2.840.03.712.6

Recent Developments

The register includes all identifiable entity-level events plus parent-level formula developments that directly concern the business.

After delisting, Yashili no longer issues HKEX announcements, and entity-level news (leadership changes, litigation, layoffs) is not publicly disclosed.*

Company Snapshot

$555.5M

Revenue

1983

Founded

Chaozhou, China

Headquarters

SWOT Analysis

Strengths

  • Parent backing: 100% owned by Mengniu (RMB 82.2bn revenue FY2025, MSCI ESG AA)
  • Retained registered China plants: Guangdong and Shanxi (Yashili) plants listed in Mengniu 2025 Annual Report
  • Innovation momentum in Reeborne: First Sn-2 DHA/ARA IMF (FY2025); organic MLCT IMF (2026)
  • Recent growth: Mengniu formula revenue +22.8% YoY in H1 2026 to RMB 2,058M
  • Simplified portfolio: Loss-making Dumex, Arla distribution and NZ unit divested in 2022–2025
  • Prior revenue ceiling shows capacity: FY2021 revenue RMB 4,434.7M, the company's record

Weaknesses

  • Persistent unprofitability before delisting: Net losses of RMB 81.4M (FY2021) and RMB 230.7M (FY2022)
  • Cash burn: Operating cash outflow of RMB 495.4M in FY2022
  • Margin compression: Gross margin fell from 32.9% to 28.1% (FY2021→FY2022)
  • Brand-acquisition failures: Dumex losses above RMB 2.3bn before 2015; up to RMB 300M impairment in 2021
  • Management instability: Industry analysts cite frequent sales-leadership change and weak incentives (Jiemian, 2022)
  • Sub-scale vs leaders: FY2020 revenue RMB 3.65bn vs Feihe RMB 18.6bn

Opportunities

  • Industry stabilisation and premium growth: Mengniu reports IMF stabilising in 2025 and leading growth in H1 2026
  • Overseas formula expansion: Mengniu targeting Southeast Asia, Australia, Middle East
  • Adult and senior nutrition: Mengniu precision-nutrition push for older consumers (2026)
  • Raw-material deep processing: Mengniu lactoferrin and high-value ingredient capacity
  • Policy support for births: China childcare subsidies (2025)
  • Consolidation: Weaker mid-tier brands exiting favour large-group players

Threats

  • Demographics: Births roughly halved since 2016 (NBS; approximate)
  • Leader dominance: Yili 18.1% IMF retail share (H1 2025); Feihe scale
  • Ex-assets now arming rivals: a2 to relaunch two ex-Yashili China-label registrations; Arla targets doubling its China IMF business
  • Milk-supply volatility: China Modern Dairy (Mengniu associate) lost RMB 1.136bn in 2025
  • Regulatory re-registration risk: 2023 GB standards required formula re-registration industry-wide
  • Parent strategic reprioritisation: Formula is only about 4–5% of Mengniu revenue; liquid milk is about 79%

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Late 2024–early 2025Parent injects ≈NZ$31M into Yashili NZSignals the NZ unit could not self-fund
2025 (NZ filing)Yashili NZ reports FY2024 loss of NZ$23.5M on revenue of NZ$57.9M (fifth consecutive loss)Prompts exit consideration
Aug 2025Mengniu H1 2025: formula revenue RMB 1.67bn (4.0% of group); management says the IMF industry is gradually stabilisingBase period for the 2026 rebound
Aug 2025Press speculation on an a2 Milk buyout of PokenoPrecursor to deal
18 Aug 2025a2 Milk announces acquisition of Yashili New Zealand Dairy for ≈NZ$282M plus a ≈NZ$100M multi-year capex plan (100+ jobs)Monetises the NZ registration assets
18 Aug 2025a2 plans to relaunch the two China-label registrations under the a2 brand within 12–18 monthsFormer Yashili registrations become a competitor's asset
Aug 2025NZ Overseas Investment Office approval for the saleRegulatory clearance
~1–4 Sep 2025Sale completedYashili exits New Zealand
Sep 2025 onwarda2 starts SAMR amendment applications for the two registrations (up to 12 months)Transition of the registrations to a2
Feb 2026a2 H1 FY26: Pokeno price reduced to ≈NZ$275M after a completion adjustment in a2's favourFinal consideration lower than headline
13 Mar 2026Broker previews (e.g., Emperor Capital) on Mengniu FY25 impairments and earnings normalisationParent context
20–25 Mar 2026Mengniu FY2025 results: revenue RMB 82.2bn (−7.3%); milk powder cited among double-digit growth categoriesFormula business returns to growth
26 Mar 2026Mengniu FY2025 press release: Reeborne Sn-2 DHA/ARA launch; DHA algal-oil formulation patentInnovation narrative
Apr 2026Mengniu 2025 Annual Report lists Guangdong (Yashili) and Shanxi (Yashili) plantsConfirms retained China manufacturing footprint
Mar 2026Mengniu reaffirms overseas expansion in formula and cheese (Southeast Asia, Australia, Middle East)Possible export outlet for Yashili plants
Aug 2026Mengniu H1 2026: formula revenue RMB 2,058M, up 22.8% YoY (4.6% of group, +0.6pp)Strongest formula growth in years
Aug 2026Reeborne launches organic MLCT infant formula; infant formula described as leading industry growthProduct cadence continues
2026Mengniu highlights precision nutrition for middle-aged and older consumers in milk powderAdult powder diversification

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

6 charts
Revenue by Segment (FY2020–FY2022): Total revenue rose from CNY 3,649 Mn in FY2020 to CNY 3,738.2 Mn in FY2022.
Yashili International Holdings Ltd — Revenue by Segment (FY2020–FY2022)
Series (CNY Mn)FY2020FY2021FY2022
Total revenue3,6494,434.73,738.2
Milk powder products—3,6512,968
Other milk powder products ( residual)—438512
Nutrition / brewing products (冲调)—221195
Others—12563

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.